Decontamination of Two Umbilical Cord Blood Grafts Prior to Autologous Administration.
Journal
Maedica
ISSN: 1841-9038
Titre abrégé: Maedica (Bucur)
Pays: Romania
ID NLM: 101526930
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
entrez:
23
2
2023
pubmed:
24
2
2023
medline:
24
2
2023
Statut:
ppublish
Résumé
Umbilical cord blood (UCB) is proving to be a valuable resource of stem cells and is currently being used for a variety of oncological and hematological pathologies and metabolic disorders; in addition, new clinical trials are showing promising results in certain neurological, autoimmune and developmental disorders. More recently, the US Food and Drug Administration (FDA) has granted approval for the clinical use of cellular therapies with UCB-based products and new therapeutic utilizations are being studied for regenerative medicine; all these developments will increase the utilization of "off-the-shelf" UCB units. As a drawback, contamination of UCB grafts is a significant occurrence (upwards of 5% in most analysis) and, even though it consists mainly of non-pathogenic bacteria, it can raise serious questions regarding intravenous UCB administration, especially in patients who are not receiving coincidental antibiotic coverage. Here we report the successful decontamination of two UCB grafts prior to administration without compromising the viability of the stem cells administered, and propose to apply the same principle and procedure to any contaminated graft.
Identifiants
pubmed: 36818273
doi: 10.26574/maedica.2022.17.4.885
pmc: PMC9923064
doi:
Types de publication
Editorial
Langues
eng
Pagination
885-892Références
Transfusion. 2012 Aug;52(8):1770-7
pubmed: 22211719
Stem Cells Transl Med. 2022 Jun 22;11(6):604-612
pubmed: 35486383
Transfus Med. 2022 Feb;32(1):82-87
pubmed: 34862686
Cold Spring Harb Perspect Med. 2016 Sep 01;6(9):
pubmed: 27481773
J Leukoc Biol. 2003 Dec;74(6):998-1007
pubmed: 12972509
Transfusion. 2007 Apr;47(4):636-43
pubmed: 17381622
Transfusion. 2005 Jun;45(6):874-8
pubmed: 15934984
Cytotherapy. 2014 Aug;16(8):1153-7
pubmed: 24582458
Biochim Biophys Acta. 2010 Sep;1800(9):956-63
pubmed: 20417254
J Antimicrob Chemother. 1999 Mar;43(3):399-402
pubmed: 10223596
Transfus Med. 2013 Dec;23(6):438-41
pubmed: 24118280
Blood. 2016 May 12;127(19):2346-54
pubmed: 26968535
J Pharmacobiodyn. 1980 Oct;3(10):493-9
pubmed: 6970806
Dev Biol Stand. 1987;66:23-8
pubmed: 3582752
Lancet Haematol. 2020 Feb;7(2):e134-e145
pubmed: 31704264
Nouv Rev Fr Hematol (1978). 1990;32(6):423-5
pubmed: 1983224
Blood. 2008 Oct 1;112(7):2979-89
pubmed: 18587012
Vox Sang. 1998;74(2):88-94
pubmed: 9501406
Transfusion. 2014 Feb;54(2):340-52
pubmed: 23711284
Front Cell Dev Biol. 2022 Apr 04;10:835793
pubmed: 35445027
Transfusion. 2017 Aug;57(8):1956-1967
pubmed: 28474347
Transfusion. 2014 Mar;54(3):550-9
pubmed: 23889674
J Pharmacol Toxicol Methods. 2018 May - Jun;91:1-6
pubmed: 29288713
Mol Ther Methods Clin Dev. 2022 Apr 13;25:410-424
pubmed: 35573051
Biol Blood Marrow Transplant. 2002;8(7):368-76
pubmed: 12171483
mBio. 2017 Feb 7;8(1):
pubmed: 28174311
PLoS One. 2015 Oct 29;10(10):e0141152
pubmed: 26512991
Vox Sang. 2002 Jan;82(1):32-8
pubmed: 11856465
N Engl J Med. 1996 Jul 18;335(3):157-66
pubmed: 8657213
Equine Vet J. 2013 Nov;45(6):732-6
pubmed: 23448189
J Vis Exp. 2012 May 07;(63):e3627
pubmed: 22588077
Blood. 2013 Jul 25;122(4):491-8
pubmed: 23673863
Blood Adv. 2019 Jul 23;3(14):2057-2068
pubmed: 31292125
Mol Ther Methods Clin Dev. 2021 Jan 26;20:542-550
pubmed: 33665224
Stem Cell Res Ther. 2022 Jun 11;13(1):246
pubmed: 35690786
Transfusion. 2015 Aug;55(8):1985-92
pubmed: 25757514
N Engl J Med. 1989 Oct 26;321(17):1174-8
pubmed: 2571931
Stem Cell Rev Rep. 2020 Aug;16(4):628-638
pubmed: 32424674
F1000Res. 2017 Aug 24;6:1556
pubmed: 28928957
Biol Blood Marrow Transplant. 2006 Nov;12(11):1142-9
pubmed: 17085307
Proc Natl Acad Sci U S A. 1995 Oct 24;92(22):10119-22
pubmed: 7479737
Stem Cells Transl Med. 2021 Nov;10 Suppl 2:S62-S74
pubmed: 34724722